Skip to main content

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

Agency: National Institutes of Health

Assistance Listings
  • 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
  • 93.395 -- Cancer Treatment Research
  • 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research
  • 93.279 -- Drug Use and Addiction Research Programs
  • 93.273 -- Alcohol Research Programs
  • 93.233 -- National Center on Sleep Disorders Research
  • 93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
  • 93.839 -- Blood Diseases and Resources Research
  • 93.213 -- Research and Training in Complementary and Integrative Health
  • 93.837 -- Cardiovascular Diseases Research
  • 93.838 -- Lung Diseases Research
  • 93.865 -- Child Health and Human Development Extramural Research
  • 93.866 -- Aging Research
  • 93.867 -- Vision Research

Open opportunityLast Updated: Jun 16, 2026

Important dates

  • Closing: February 20, 2029

Award details

  • Expected project funding: $11,000,000
  • Expected awards: 3

Award min.

Not specified

Award max.

Not specified

  • Funding opportunity number:RFA-NS-27-007
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Cooperative agreement
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Posted date: June 16, 2026
  • Archive date: April 21, 2029
  • Version: 1

View version history on Grants.gov

The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope...

Eligibility

Education

  • Private institutions of higher education
  • Public and state institutions of higher education
  • Independent school districts

Government

  • Federally recognized Native American tribal governments
  • Public and Indian housing authorities
  • Special district governments
  • State governments
  • County governments
  • City or township governments

Miscellaneous

  • Other

Nonprofit

  • Nonprofits non-higher education with 501(c)(3)
  • Nonprofits non-higher education without 501(c)(3)
  • Other Native American tribal organizations

Business

  • For-profit organizations other than small businesses
  • Small businesses

Additional information on eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Documents

File nameDescriptionLast updated
RFA-NS-27-007-Full-Announcement.html
RFA-NS-27-007-Full-Announcement.html
Jun 16, 2026 03:42 PM UTC

Agency contact information

Email: PTDP@ninds.nih.gov

PTDP@ninds.nih.gov

National Institute of Neurological Disorders and Stroke (NINDS) PTDP@ninds.nih.gov

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov